JP5201744B2 - 眼内注射装置 - Google Patents
眼内注射装置 Download PDFInfo
- Publication number
- JP5201744B2 JP5201744B2 JP2009545174A JP2009545174A JP5201744B2 JP 5201744 B2 JP5201744 B2 JP 5201744B2 JP 2009545174 A JP2009545174 A JP 2009545174A JP 2009545174 A JP2009545174 A JP 2009545174A JP 5201744 B2 JP5201744 B2 JP 5201744B2
- Authority
- JP
- Japan
- Prior art keywords
- injection device
- intraocular injection
- syringe
- eye
- hollow body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007924 injection Substances 0.000 title claims description 237
- 238000002347 injection Methods 0.000 title claims description 237
- 230000033001 locomotion Effects 0.000 claims description 29
- 239000002344 surface layer Substances 0.000 claims description 29
- 239000010410 layer Substances 0.000 claims description 23
- 125000006850 spacer group Chemical group 0.000 claims description 12
- 210000004087 cornea Anatomy 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 10
- 210000003786 sclera Anatomy 0.000 claims description 10
- 230000001681 protective effect Effects 0.000 claims description 8
- 210000001232 limbus corneae Anatomy 0.000 claims description 5
- 230000001846 repelling effect Effects 0.000 claims description 4
- 210000001508 eye Anatomy 0.000 description 120
- 238000000034 method Methods 0.000 description 56
- 239000003814 drug Substances 0.000 description 50
- 108091006146 Channels Proteins 0.000 description 44
- 229940079593 drug Drugs 0.000 description 41
- 230000001225 therapeutic effect Effects 0.000 description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
- 239000000203 mixture Substances 0.000 description 21
- 201000010099 disease Diseases 0.000 description 18
- 238000011282 treatment Methods 0.000 description 17
- 208000035475 disorder Diseases 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 14
- 239000012530 fluid Substances 0.000 description 14
- 230000003110 anti-inflammatory effect Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 210000001525 retina Anatomy 0.000 description 12
- 206010029113 Neovascularisation Diseases 0.000 description 10
- 239000000126 substance Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 208000010412 Glaucoma Diseases 0.000 description 7
- 108010025020 Nerve Growth Factor Proteins 0.000 description 7
- 206010064930 age-related macular degeneration Diseases 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 208000002780 macular degeneration Diseases 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 208000022873 Ocular disease Diseases 0.000 description 6
- 210000003161 choroid Anatomy 0.000 description 6
- 210000000695 crystalline len Anatomy 0.000 description 6
- 208000030533 eye disease Diseases 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 210000000554 iris Anatomy 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000004127 vitreous body Anatomy 0.000 description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 108090000467 Interferon-beta Proteins 0.000 description 5
- 102000007072 Nerve Growth Factors Human genes 0.000 description 5
- 239000004037 angiogenesis inhibitor Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003527 fibrinolytic agent Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- -1 medorizone Chemical compound 0.000 description 5
- 239000003900 neurotrophic factor Substances 0.000 description 5
- 238000003825 pressing Methods 0.000 description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 description 4
- 241000289659 Erinaceidae Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000001344 Macular Edema Diseases 0.000 description 4
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 4
- 206010046851 Uveitis Diseases 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 210000005252 bulbus oculi Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 229960000103 thrombolytic agent Drugs 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 3
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102100026720 Interferon beta Human genes 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108090000099 Neurotrophin-4 Proteins 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000004240 ciliary body Anatomy 0.000 description 3
- 210000000795 conjunctiva Anatomy 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003966 growth inhibitor Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000004090 neuroprotective agent Substances 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000002525 vasculotropin inhibitor Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102400000068 Angiostatin Human genes 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 2
- 208000002691 Choroiditis Diseases 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 206010058202 Cystoid macular oedema Diseases 0.000 description 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 208000035620 Eye penetration Diseases 0.000 description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 102000004230 Neurotrophin 3 Human genes 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 208000003971 Posterior uveitis Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
- 208000007135 Retinal Neovascularization Diseases 0.000 description 2
- 201000007527 Retinal artery occlusion Diseases 0.000 description 2
- 201000007737 Retinal degeneration Diseases 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 description 2
- 206010038935 Retinopathy sickle cell Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 108010041776 cardiotrophin 1 Proteins 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 201000010206 cystoid macular edema Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000011190 diabetic macular edema Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 229940043075 fluocinolone Drugs 0.000 description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 201000003142 neovascular glaucoma Diseases 0.000 description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 201000007407 panuveitis Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000004258 retinal degeneration Effects 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 239000000790 retinal pigment Substances 0.000 description 2
- 208000004644 retinal vein occlusion Diseases 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000006492 vascular dysfunction Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- ARXHSOGUAABXQR-UHFFFAOYSA-N 2-iodophosphinine Chemical compound IC1=CC=CC=P1 ARXHSOGUAABXQR-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000008516 Capsule Opacification Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229940122853 Growth hormone antagonist Drugs 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102100026019 Interleukin-6 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000014413 Neuregulin Human genes 0.000 description 1
- 108050003475 Neuregulin Proteins 0.000 description 1
- 102400000058 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 102100033857 Neurotrophin-4 Human genes 0.000 description 1
- 102100021584 Neurturin Human genes 0.000 description 1
- 108010015406 Neurturin Proteins 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 229960004266 acetylcholine chloride Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000028600 axonogenesis Effects 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000004340 degenerative myopia Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 208000011325 dry age related macular degeneration Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 230000000193 eyeblink Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 210000004083 nasolacrimal duct Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 108091008601 sVEGFR Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000033504 synapse organization Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3287—Accessories for bringing the needle into the body; Automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/42—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
- A61M5/427—Locating point where body is to be pierced, e.g. vein location means using ultrasonic waves, injection site templates
Description
前記眼内注射装置600は、プレート610と、支持体620と、注射器630を含む。
2 下層部
100 眼内注射装置
110 プレート
111 眼支持面
112 開口部
113 欠切部
114 縁部
120 支持体
121 中空体
122 案内チャネル
123 環状フランジ
124 第1の座面
125 第2の座面
130 注射器
131 注射筒
132 射器プランジャ
133 注射針
134 針支持体
135 環状リム
136 環状リム
137 拡大部
140 弾性部材
141 可撓性のある脚部
142 歯部
200 眼内注射装置
210 プレート
211 眼支持面
212 開口部
213 欠切部
214 縁部
220 支持体
221 中空体
222 案内チャネル
223 環状フランジ
224 座面
227 ハウジング
228 蓋
229 プッシュボタン
230 注射器
231 注射筒
232 注射器プランジャ
233 注射針
234 針支持体
235 環状リム
236 環状リム
237 拡大部
238 指状体
240 弾性部材
241 可撓性のある脚部
242 歯部
250 解除可能な接続手段
251 スペーサー
252 弾性オープンリング
253 長手方向の溝
260 着脱可能なキャップ
300 眼内注射装置
310 プレート
311 眼支持面
312 開口部
313 欠切部
314 縁部
320 支持体
321 中空体
322 案内チャネル
323 環状フランジ
324 座面
327 ハウジング
328 蓋
329 プッシュボタン
330 注射器
331 注射筒
332 注射器プランジャ
333 注射針
334 針支持体
335 環状リム
336 環状リム
337 拡大部
338 指状体
339 保護キャップ
340 弾性部材
341 可撓性のある脚部
342 歯部
350 解除可能な接続手段
351 スペーサー
352 弾性オープンリング
353 長手方向の溝
370 着脱可能な防止リング
371 カープル
400 眼内注射装置
410 プレート
411 眼支持面
412 開口部
413 欠切部
414 縁部
420 支持体
421 中空体
4211 内側部
4212 外側部
4213 ロック部材
4214 ボタン
4215 スロット
4216 ヒンジ
4217 ロッキング・ラグ
4218 摩擦脚部
4219 バルジ
4220 溝
422 案内チャネル
425 座面
428 蓋
4281 保持脚部
430 注射器
431 注射筒
432 注射器プランジャ
433 注射針
434 針支持体
435 環状リム
437 拡大部
438 指状体
441 可撓性のある脚部
442 歯部
454 つる巻きバネ
500 眼内注射装置
510 プレート
511 眼支持面
512 開口部
513 欠切部
514 縁部
520 支持体
521 中空体
5211 内側部
5212 外側部
5213 ロック部材
5214 ロック脚部
5215 ロック解除部材
5216 ロック解除脚部
5217 ロック歯部
5218 ロック解除歯部
5220 開口部
522 案内チャネル
525 座面
528 蓋
5281 保持脚部
530 注射器
531 注射筒
532 注射器プランジャ
533 注射針
534 針支持体
535 環状リム
537 拡大部
538 指状体
541 可撓性のある脚部
542 歯部
554 つる巻きバネ
600 眼内注射装置
610 プレート
611 眼支持面
612 開口部
613 欠切部
614 縁部
620 支持体
621 中空体
6211 内側部
6212 外側部
6213 ロック部材
6214 脚部
6215 ロック・フォーク
6216 側方分岐部
6217 端部
6220 溝
622 案内チャネル
625 座面
628 蓋
6281 保持脚部
630 注射器
631 注射筒
632 注射器プランジャ
633 注射針
634 針支持体
635 環状リム
637 拡大部
638 指状体
641 可撓性のある脚部
642 歯部
654 つる巻きバネ
700 眼内注射装置
710 プレート
711 座面
712 開口部
720 支持体
721 中空体
7211 内側部
7212 外側部
722 案内チャネル
730 注射器
731 注射筒
732 注射器プランジャ
733 注射針
734 針支持体
737 拡大部
740 弾性部材
741 可撓性のある脚部
754 つる巻きバネ
700' 眼内注射装置
7211' 外側部
7212' 内側部
700'' 眼内注射装置
728'' アダプター
700''' 眼内注射装置
700'''' 眼内注射装置
Claims (35)
- 眼に接触させるのに適合されたプレート(110,210,310)と、眼の内部に針(133,233,333)を案内するための案内手段 (120,220,320)とを含む眼内注射のための装置(100,200,300)であって、
前記眼の内部に前記針(133,233,333)が案内される前で前記プレート(110,210,310)が前記眼と接触する際に、前記眼の下層部(2)に対して前記眼の表層部(1)を移動させるための手段(140,240, 340)を含むことを特徴とする眼内注射装置。 - 請求項1の眼内注射装置において、
前記下層部(2)に対して前記表層部(1)を移動させるための前記手段は、前記表層部(1)に対して付勢される時に曲げることのできる弾性部材(140,240,340)を含み、それにより前記弾性部材(140,240,340)は前記表層部(1)に接線分力を加えることを特徴とする眼内注射装置。 - 請求項2の眼内注射装置において、
前記弾性部材(140,240,340)は前記プレート(110,210,310)から突出した、可撓性を有する脚部(141,241,341)を含むことを特徴とする眼内注射装置。 - 請求項2又は請求項3のいずれか1つの眼内注射装置において、
下層部(2)に対して眼の表層部(1)を移動させる前記手段(140,240,340)は、前記表層部(1)を係合させるための手段(142,242,342)を含むことを特徴とする眼内注射装置。 - 請求項4の眼内注射装置において、
前記表層部を係合させるための前記手段は少なくとも1つの歯部(142,242,342)を含むことを特徴とする眼内注射装置。 - 請求項3及び請求項5の眼内注射装置において、
前記歯部(142,242,342)は前記可撓性を有する脚部(141,241,341)の自由端部に設けられていることを特徴とする眼内注射装置。 - 請求項1乃至請求項6のいずれか1つの眼内注射装置において、
前記プレート (110,210,310)は前記眼の角膜と強膜を定める角膜輪部に沿って位置するように適合された縁部(114,214,314)を有する欠切部(113,213,313)を含み、前記角膜輪部に対して前記案内手段(120,220,320)の位置を調整することを特徴とする眼内注射装置。 - 請求項7の眼内注射装置において、
前記欠切部(113,213,313)の前記縁部(114,214,314)は実質的に円形であることを特徴とする眼内注射装置。 - 請求項7又は8の眼内注射装置において、
前記欠切部(113,213,313)の前記縁部(114,214,314)は、前記縁部(114,214,314)が前記角膜輪部に重ね合わせられることができるように前記角膜輪部と対応する形を有することを特徴とする眼内注射装置。 - 請求項9の眼内注射装置において、
前記欠切部(113,213,313)の前記縁部(114,214,314)が前記角膜輪部に重ね合わせられる際、前記プレート (110,210,310)が前記眼の強膜まで伸びるように、前記欠切部(113,213,313)は前記プレート(110,210,310)に配置されていることを特徴とする眼内注射装置。 - 請求項7乃至請求項10のいずれか1つの眼内注射装置において、
前記針(133,233,333)が、前記角膜輪部から約3.5mmの距離に、強膜を介して前記眼に入り込むように、前記欠切部 (113,213,313)と前記案内手段 (120,220,320)とが配置されていることを特徴とする眼内注射装置。 - 請求項1乃至請求項11のいずれか1つの眼内注射装置において、
前記プレート (110,210,310)が前記眼の外表面を合わせて支持するための曲線形状を呈する眼支持面(111,211,311)を有することを特徴とする眼内注射装置。 - 請求項1乃至請求項12のいずれか1つの眼内注射装置において、
前記案内手段は注射器(130,230,330)の筒(131,231,331)を収容するのに適合された中空体 (121,221,321)を有する支持体(120,220,320)を含み、前記注射器(130,230,330)が前記中空体 (121,221,321)に対してスライドさせることができることを特徴とする眼内注射装置。 - 請求項13の眼内注射装置において、
前記注射器(130,230,330)は、前記注射器(130,230,330)の針(133,233,333)が前記中空体 (121,221,321)の中に収納されている収納位置から、前記針(133,233,333)が前記中空体(121,221,321)の外へ突き出る注射位置まで、前記中空体(121,221,321)に対して移動可能であることを特徴とする眼内注射装置。 - 請求項14の眼内注射装置において、
注射筒(131,231,331)と注射器プランジャ(132,232,332)とを含み、前記中空体 (121,221,321)に収納された前記注射器(130,230,330)のプランジャ(132,232,332)を操作することにより、前記注射器(130,230,330)を前記注射位置の方にスライドさせ、次に連続して前記筒(131,231,331)に対して前記プランジャ(132,232,332)をスライドさせること特徴とする眼内注射装置。 - 請求項14又は請求項15のいずれか1つの眼内注射装置において、
前記支持体 (130,230,330) は、前記注射筒のリム(135,235,335)が当接することのできる座面 (134,234,334)を含み、前記注射器のプランジャ(132,232,332)を操作することにより、前記注射器を、前記筒の前記リム(135,235,335)が前記座面 (134,234,334)に当接するまで、前記中空体(121,221,321)に対して前記注射位置の方にスライドさせ、次に連続して前記プランジャ(132,232,332)を前記注射筒(131,231,331)にスライドさせることを特徴とする眼内注射装置。 - 請求項14乃至請求項16のいずれか1つの眼内注射装置において、
前記中空体 (221,321)に対する共通のスライドの動きにおいて前記注射器(230,330) の前記注射器プランジャ(232,332)と前記注射筒(231,331)とを接続し、前記中空体 (221,321)に対する前記注射器(230,330)の所定の位置で前記接続を解除するための解除可能な接続手段(250,350)を含むことを特徴とする眼内注射装置。 - 請求項17の眼内注射装置において、
前記解除可能な接続手段(250,350)は、前記中空体 (221,321)の内壁に対して圧縮応力を与えられている、少なくとも1つの弾性部材(252,352)を含み、前記内壁は、前記注射器(230,330)が前記弾性部材(252,352)を解放する所定の位置に到達する際に前記弾性部材(252,352)を収容するためのハウジングを有し、それにより前記プランジャ(232,332)は前記筒(231,331)に対して動くことが許されることを特徴とする眼内注射装置。 - 請求項18の眼内注射装置において、
前記解除可能な接続手段(250,350)は、前記筒(231,331)に対する前記プランジャ(232,332)のスライドの動きを防ぐために、前記注射筒(231,331)と前記注射器プランジャ(232,332)との間に設けられたスペーサー(251,351)を含むことを特徴とする眼内注射装置。 - 請求項18及び請求項19の眼内注射装置において、
前記スペーサー (251,351)は前記プランジャ(253,353)の指状体(238,338)を収納するための溝(253,353)を有し、前記圧縮応力が与えられている弾性部材(252,352)は前記弾性部材(252,352)が解除されるまで前記溝(253,353)において前記指状体(238,338)がスライドするのを防ぐのに適合されていることを特徴とする眼内注射装置。 - 請求項14乃至請求項20のいずれか1つの眼内注射装置において、
前記プランジャ(232,332)を操作するためのプッシュボタン(229,329)を含むことを特徴とする眼内注射装置。 - 請求項13乃至請求項21のいずれか1つの眼内注射装置において、
前記支持体(120,220,320)は、前記中空体(121,221,321)から外へ突き出たフィンガーベアリングフランジ(123,223,323)を含み、操作者が、前記中空体(121,221,321)に対して前記注射器(130,230,330)をスライドさせる際に、前記支持体(120,220,320)を保持するようにすることを特徴とする眼内注射装置。 - 請求項1乃至請求項22のいずれか1つの眼内注射装置において、
注射筒(331)と注射針(333)とを含み、前記注射筒(331)は保護キャップ(339)で封止されたカープル(371)を含み、前記針(333)は、組み立てられた注射器(330)を注射位置の方に動かす前に前記注射器(330)を組み立てるために前記筒(331)に前記針(333)を接続させ、同時に前記針(333)で前記保護キャップ(339)に孔を開けるための前記カープル(371)に対して後方へ動くことができることを特徴とする眼内注射装置。 - 請求項23の眼内注射装置において、
前記注射針(333)を支持するための針支持体 (334)を含み、前記針支持体 (334)は、前記保護キャップ(339)に孔を開けるため、前記カープル(371)に対して前記針(333)を動かすべく前記中空体(321)の外から操作されることができることを特徴とする眼内注射装置。 - 請求項23又は請求項24の眼内注射装置において、
前記中空体(321)に対して前記針(333)の動きを防ぐための着脱可能な防止リング(370)を含むことを特徴とする眼内注射装置。 - 請求項1乃至請求項25のいずれか1つの眼内注射装置において、
前記案内手段は中空体 (421,521,621,721)を有する支持体(420,520,620,720)を含み、前記中空体(421,521,621,721)は固定部 (4211,5211,6211,7211) と、前記固定部 (4211,5211,6211,7211)に対してスライドすることのできる可動部 (4212,5212,6212,7212)とを有し、前記可動部 (4212,5212,6212,7212)は注射器(430,530,630,730)の筒(431,531,631,731)を収納するために適合されており、前記注射器(430,530,630,730)と前記可動部 (4212,5212,6212,7212)が前記固定部(4211,5211,6211,7211)に対して共通にスライドの動きができることを特徴とする眼内注射装置。 - 請求項26の眼内注射装置において、
前記固定部 (4211,5211,6211)に対して前記可動部 (4212,5212,6212)の不意の動きを防ぐためのロック部材 (4213,5213,6213)を含むことを特徴とする眼内注射装置。 - 請求項27の眼内注射装置において、
前記ロック部材 (4213,5213,6213)はロック用凹部(4220,5220,6220)に収容可能なロック用突起(4217,5217,6217)を含み、前記眼内注射装置は 前記ロック用凹部(4220,5220,6220)から前記ロック用突起(4217,5217,6217)を取り外すための手段(4214,5215,6214)を含み、そのことにより前記固定部 (4211,5211,6211)に対して前記可動部 (4212,5212,6212)が動くようにさせることを特徴とする眼内注射装置。 - 請求項26又は請求項27のいずれか1つの眼内注射装置において、
前記可動部 (4212,5212,6212)は前記固定部 (4211,5211,6211)を取り囲むことを特徴とする眼内注射装置。 - 請求項26乃至請求項29のいずれか1つの眼内注射装置において、
前記固定部 (4211,5211) と前記可動部 (4212,5212)との間に摩擦を発生させることにより前記固定部 (4211,5211)に対する前記可動部 (4212,5212)の動きを遅くさせる摩擦部材(4218,5217)を含むことを特徴とする眼内注射装置。 - 請求項26乃至請求項30のいずれか1つの眼内注射装置において、
前記注射器(430,530,630)のプランジャ(432,532,632)と前記可動部 (4212,5212,6212)との間に配置された弾性部材(454,554,654)を含み、前記弾性部材(454,554,654)は前記注射器(430,530,630)の前記筒(431,531,631)に対して前記プランジャ(432,532,632)のスライドの動きに反発する復元力を与えるのに適合されていることを特徴とする眼内注射装置。 - 請求項31の眼内注射装置において、
前記可動部 (4212,5212,6212)を操作することにより、前記固定部 (4211,5211,6211)に対して前記可動部 (4212,5212,6212)をスライドさせ、次に連続して前記筒(431,531,631)に対して前記プランジャ(432,532,632)をスライドさせることを特徴とする眼内注射装置。 - 請求項26乃至請求項30のいずれか1つの眼内注射装置において、
前記固定部 (7211)と前記可動部 (7212)との間に配置された弾性部材(754)を含み、前記弾性部材(754)は前記固定部 (7211)に対して前記可動部 (7212)のスライドの動きに反発する復元力を与えるのに適合されていることを特徴とする眼内注射装置。 - 請求項33の眼内注射装置において、
前記注射器 (730)のプランジャ(732)を操作することにより、前記復元力がある所定の限界に達するまで連続して前記固定部 (7211)に対して前記可動部 (7212)を動かし、次に連続して前記筒(731)に対して前記プランジャ(732)を動かすことを特徴とする眼内注射装置。 - 請求項31乃至請求項34のいずれか1つの眼内注射装置において、
前記弾性部材(454,554,654,754)は、注射の後、前記注射器(430,530,630,730)を前記中空体(421,521,621,721)に自発的に戻させる復元力を与えることを特徴とする眼内注射装置。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07360001.7 | 2007-01-09 | ||
EP07360002 | 2007-01-09 | ||
EP07360002.5 | 2007-01-09 | ||
EP07360001 | 2007-01-09 | ||
PCT/EP2008/050206 WO2008084064A1 (en) | 2007-01-09 | 2008-01-09 | Apparatus for intra-ocular injection |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010515505A JP2010515505A (ja) | 2010-05-13 |
JP5201744B2 true JP5201744B2 (ja) | 2013-06-05 |
Family
ID=39295018
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009545174A Active JP5201744B2 (ja) | 2007-01-09 | 2008-01-09 | 眼内注射装置 |
JP2009545173A Expired - Fee Related JP5201743B2 (ja) | 2007-01-09 | 2008-01-09 | 眼内注射装置 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009545173A Expired - Fee Related JP5201743B2 (ja) | 2007-01-09 | 2008-01-09 | 眼内注射装置 |
Country Status (6)
Country | Link |
---|---|
US (2) | US8460242B2 (ja) |
EP (2) | EP2124857B1 (ja) |
JP (2) | JP5201744B2 (ja) |
CA (2) | CA2674891C (ja) |
DK (2) | DK2124857T3 (ja) |
WO (2) | WO2008084064A1 (ja) |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7867186B2 (en) | 2002-04-08 | 2011-01-11 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
US6638239B1 (en) | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
ES2304438T3 (es) | 2001-04-07 | 2008-10-16 | Glaukos Corporation | Stent de glaucoma para el tratamiento del glaucoma. |
US7331984B2 (en) | 2001-08-28 | 2008-02-19 | Glaukos Corporation | Glaucoma stent for treating glaucoma and methods of use |
US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
US8197435B2 (en) | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
CA2668954C (en) | 2006-11-10 | 2020-09-08 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US20100152646A1 (en) * | 2008-02-29 | 2010-06-17 | Reshma Girijavallabhan | Intravitreal injection device and method |
FR2928536B1 (fr) * | 2008-03-14 | 2012-04-27 | Inst Nat Sante Rech Med | Dispositif d'injection dans l'oeil |
CZ303279B6 (cs) * | 2009-02-06 | 2012-07-11 | Stodulka@Pavel | Ocní aplikátor k injekcnímu vpravování substance do tkáne oka |
ES2616853T3 (es) * | 2008-09-11 | 2017-06-14 | Pavel Stodulka | Aplicador ocular para la aplicación por inyección de una sustancia en el tejido ocular |
US7678078B1 (en) * | 2008-10-21 | 2010-03-16 | KMG Pharma LLC | Intravitreal injection device, system and method |
US8221353B2 (en) | 2008-10-21 | 2012-07-17 | KMG Pharma, Inc | Intravitreal injection device and system |
NL2002379C2 (en) * | 2008-12-29 | 2010-06-30 | D O R C Dutch Ophthalmic Res Ct International B V | An ophthalmic device and an intravitreal method. |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
PL2391419T3 (pl) | 2009-01-29 | 2019-12-31 | Forsight Vision4, Inc. | Dostarczanie leku do tylnego odcinka |
GB2474646A (en) * | 2009-10-20 | 2011-04-27 | John David Huggan | Eye injection guide means |
WO2013022801A1 (en) | 2011-08-05 | 2013-02-14 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
US9216257B2 (en) * | 2010-03-25 | 2015-12-22 | Medtronic, Inc. | Method and apparatus for guiding an external needle to an implantable device |
US8475407B2 (en) * | 2010-03-25 | 2013-07-02 | Medtronic, Inc. | Method and apparatus for guiding an external needle to an implantable device |
US8483802B2 (en) * | 2010-03-25 | 2013-07-09 | Medtronic, Inc. | Method and apparatus for guiding an external needle to an implantable device |
US9339601B2 (en) * | 2010-03-25 | 2016-05-17 | Medtronic, Inc. | Method and apparatus for guiding an external needle to an implantable device |
US9408746B2 (en) | 2010-03-31 | 2016-08-09 | Ocuject, Llc | Device and method for intraocular drug delivery |
US9320647B2 (en) | 2010-03-31 | 2016-04-26 | Ocuject, Llc | Device and method for intraocular drug delivery |
JP5931847B2 (ja) * | 2010-03-31 | 2016-06-08 | オキュジェクト, エルエルシー | 眼内薬剤送達のためのデバイスおよび方法 |
WO2011123722A1 (en) | 2010-03-31 | 2011-10-06 | Ocuject, Llc | Device and method for intraocular drug delivery |
US8574217B2 (en) | 2010-04-08 | 2013-11-05 | Kmg Pharma, Llc | Sub-mucosal agent delivery method for the eye |
US8652118B2 (en) * | 2010-04-08 | 2014-02-18 | Kmg Pharma, Llc | Sub-mucosal agent delivery, apparatus, system and method |
US9399102B2 (en) * | 2010-06-25 | 2016-07-26 | Euclid Systems Corporation | Device and method for the controlled delivery of ophthalmic solutions |
US10617557B2 (en) | 2010-08-05 | 2020-04-14 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
AU2011285545B2 (en) | 2010-08-05 | 2014-03-13 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
CA2807554C (en) | 2010-08-05 | 2021-10-26 | Forsight Vision4 Inc. | Implantable therapeutic device |
BR112013009205A2 (pt) | 2010-10-15 | 2016-07-26 | Iscience Interventional Corp | dispositivo para colocação na esclera de um olho, método para acessar o espaço supracoroidal de um olho, para acessar o espaço subretinal de um olho e para colocar um orifício dentro de um trato escleral em um olho. |
EP2446866A1 (en) * | 2010-11-02 | 2012-05-02 | Fovea Pharmaceuticals | Apparatus for injection into an eye |
US8918181B2 (en) | 2010-11-16 | 2014-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for treatment of dry eye |
US9821159B2 (en) | 2010-11-16 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Stimulation devices and methods |
EP2640360A2 (en) | 2010-11-19 | 2013-09-25 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
US10285852B2 (en) | 2010-12-02 | 2019-05-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd., The Chaim Sheba Medical Center | Subretinal delivery of therapeutic compositions |
EP2500002A1 (en) | 2011-03-17 | 2012-09-19 | Sanofi-Aventis Deutschland GmbH | Apparatus for intraocular injection |
US20140088552A1 (en) * | 2011-03-25 | 2014-03-27 | The Curators Of The University Of Missouri | Intravitreal Injection Device |
EP2510911A1 (en) | 2011-04-13 | 2012-10-17 | Sanofi-Aventis Deutschland GmbH | Apparatus for intraocular injection |
EP2510902A1 (en) * | 2011-04-15 | 2012-10-17 | Sanofi-Aventis Deutschland GmbH | Intraocular injection device |
EP2726016B1 (en) | 2011-06-28 | 2023-07-19 | ForSight Vision4, Inc. | An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye |
WO2013028936A1 (en) * | 2011-08-23 | 2013-02-28 | Itech Jv Development Company, Llc | Systems and methods for performing an injection |
EP2564819A1 (en) * | 2011-09-02 | 2013-03-06 | Sanofi-Aventis Deutschland GmbH | Intraocular injection device |
RS61758B1 (sr) | 2011-09-16 | 2021-05-31 | Forsight Vision4 Inc | Aparati za razmenu tečnosti |
EP2578191A1 (en) * | 2011-10-07 | 2013-04-10 | Sanofi-Aventis Deutschland GmbH | Apparatus for intraocular injection |
EP2578261A1 (en) * | 2011-10-07 | 2013-04-10 | Sanofi-Aventis Deutschland GmbH | Injection site indicator |
EP2578188A1 (en) * | 2011-10-07 | 2013-04-10 | Sanofi-Aventis Deutschland GmbH | Apparatus for intraocular injection |
EP2578189A1 (en) * | 2011-10-07 | 2013-04-10 | Sanofi-Aventis Deutschland GmbH | Apparatus for intraocular injection |
EP2586407A1 (en) * | 2011-10-31 | 2013-05-01 | Sanofi-Aventis Deutschland GmbH | Aid device for intraocular injection |
EP2776098B1 (en) | 2011-11-07 | 2020-03-04 | Safety Syringes, Inc. | Contact trigger release needle guard |
WO2013116061A1 (en) | 2012-02-03 | 2013-08-08 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
WO2013148275A2 (en) | 2012-03-26 | 2013-10-03 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US9504603B2 (en) * | 2012-04-02 | 2016-11-29 | Ocuject, Llc | Intraocular delivery devices and methods therefor |
US9421129B2 (en) * | 2012-04-02 | 2016-08-23 | Ocuject, Llc | Intraocular delivery devices and methods therefor |
CN102895731A (zh) * | 2012-09-12 | 2013-01-30 | 广州军区广州总医院 | 一种玻璃体腔注射装置 |
KR20150083117A (ko) | 2012-11-08 | 2015-07-16 | 클리어사이드 바이오메디컬, 인코포레이드 | 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치 |
EP2967817B1 (en) * | 2013-03-12 | 2021-03-10 | Oculeve, Inc. | Implant delivery devices and systems |
EP2968113B8 (en) | 2013-03-14 | 2020-10-28 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
US9772059B2 (en) | 2013-03-14 | 2017-09-26 | Lmk Technologies, Llc | Method of dispensing a material |
US9163770B2 (en) | 2013-03-14 | 2015-10-20 | Lmk Technologies, Llc | Method and apparatus for lining a pipe |
US20140276568A1 (en) * | 2013-03-15 | 2014-09-18 | Morris Elijah Worden | Systems and methods for dampening friction in an autoinjector device |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
EP2781207A1 (en) | 2013-03-21 | 2014-09-24 | Christian Simader | Apparatus for application on an eye |
US9526654B2 (en) | 2013-03-28 | 2016-12-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
WO2014172693A2 (en) | 2013-04-19 | 2014-10-23 | Oculeve, Inc. | Nasal stimulation devices and methods |
BR112015027762A2 (pt) | 2013-05-03 | 2017-08-29 | Clearside Biomedical Inc | Aparelho e métodos para injeção ocular |
WO2014197317A1 (en) * | 2013-06-03 | 2014-12-11 | Clearside Biomedical, Inc. | Apparatus and methods for drug delivery using multiple reservoirs |
EP2810675A1 (en) * | 2013-06-04 | 2014-12-10 | Bioftalmik, S.L. | Injector for intraocular injection |
WO2015054075A1 (en) | 2013-10-07 | 2015-04-16 | Ocuject, Llc | Intraocular delivery devices and methods therefor |
US10010447B2 (en) * | 2013-12-18 | 2018-07-03 | Novartis Ag | Systems and methods for subretinal delivery of therapeutic agents |
US11045350B2 (en) * | 2013-12-30 | 2021-06-29 | Edwin Ryan | Infusion support device and method |
EP3110405B1 (en) | 2014-02-25 | 2020-05-06 | Oculeve, Inc. | Polymer formulations for nasolacrimal stimulation |
CN106029019B (zh) * | 2014-02-26 | 2020-07-03 | 阿勒根公司 | 眼内植入体递送设备及其使用方法 |
US20150305932A1 (en) * | 2014-04-28 | 2015-10-29 | Vikas Rammohan Maturi | Intraocular Injection Guide |
US20150366311A1 (en) * | 2014-06-19 | 2015-12-24 | Coopervision International Holding Company, Lp | Protection of Contact Lenses from Microbial Contamination Caused by Handling |
JP2017524419A (ja) * | 2014-06-20 | 2017-08-31 | クリアサイド バイオメディカル,インコーポレイテッド | 薬剤送達のための挿入深さを制御するための可変径カニューレ及び方法 |
US10258503B2 (en) * | 2014-07-15 | 2019-04-16 | Forsight Vision4, Inc. | Ocular implant delivery device and method |
ES2792856T3 (es) | 2014-07-25 | 2020-11-12 | Oculeve Inc | Patrones de estimulación para tratar la sequedad ocular |
US9474756B2 (en) | 2014-08-08 | 2016-10-25 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
USD750223S1 (en) | 2014-10-14 | 2016-02-23 | Clearside Biomedical, Inc. | Medical injector for ocular injection |
US9764150B2 (en) | 2014-10-22 | 2017-09-19 | Oculeve, Inc. | Contact lens for increasing tear production |
EP3209371A4 (en) | 2014-10-22 | 2018-10-24 | Oculeve, Inc. | Implantable nasal stimulator systems and methods |
JP6735742B2 (ja) | 2014-10-22 | 2020-08-05 | オキュリーブ, インコーポレイテッド | ドライアイの治療のための刺激装置及び方法 |
US20160120694A1 (en) * | 2014-11-03 | 2016-05-05 | Matthew Edward Carr | Injection instrument and method |
SG11201703726XA (en) | 2014-11-10 | 2017-06-29 | Forsight Vision4 Inc | Expandable drug delivery devices and method of use |
WO2016077497A1 (en) * | 2014-11-11 | 2016-05-19 | Eye-Vation, Llc | Delivery device |
US10588780B2 (en) * | 2015-03-04 | 2020-03-17 | Alcon Inc. | Intraocular lens injector |
FR3036289B1 (fr) * | 2015-05-19 | 2021-10-22 | Peter Cumbo | Dispositif d'injection de produit injectable comportant une canule coulissant dans une aiguille et systeme utilisant un tel dispositif |
KR20210077010A (ko) * | 2015-06-03 | 2021-06-24 | 아큐시스, 인코포레이티드 | 안구내 션트의 외부 배치 |
NL2015198B1 (en) * | 2015-07-21 | 2017-02-07 | Mechiel Hubert Schellekens Kari | Intravitreal injection device and bevacizumab for use in a method of preventing, treating or delaying macular degeneration or macular diabetic edema. |
WO2017053832A1 (en) * | 2015-09-25 | 2017-03-30 | Ryan Edwin | Dynamic support for ophthalmic device |
CA3005238A1 (en) | 2015-11-20 | 2017-05-26 | Forsight Vision4, Inc. | Porous structures for extended release drug delivery devices |
US10426958B2 (en) | 2015-12-04 | 2019-10-01 | Oculeve, Inc. | Intranasal stimulation for enhanced release of ocular mucins and other tear proteins |
EP3413851B1 (en) | 2016-02-10 | 2023-09-27 | Clearside Biomedical, Inc. | Packaging |
US10485577B2 (en) | 2016-02-18 | 2019-11-26 | Synergetics Usa, Inc. | Surgical device with triggered propulsion system for inserting a trocar-cannula assembly |
US11382657B2 (en) | 2016-02-18 | 2022-07-12 | Synergetics Usa, Inc. | Surgical devices with triggered propulsion system for inserting a trocar-cannula assembly |
WO2017143184A1 (en) * | 2016-02-18 | 2017-08-24 | Synergetics Usa, Inc. | Surgical devices with triggered propulsion system for inserting a trocar-cannula assembly |
US10252048B2 (en) | 2016-02-19 | 2019-04-09 | Oculeve, Inc. | Nasal stimulation for rhinitis, nasal congestion, and ocular allergies |
CN109195556B (zh) | 2016-04-05 | 2021-03-26 | 弗赛特影像4股份有限公司 | 可植入眼睛药物递送装置 |
CA3022683A1 (en) | 2016-05-02 | 2017-11-09 | Oculeve, Inc. | Intranasal stimulation for treatment of meibomian gland disease and blepharitis |
CA3062845A1 (en) | 2016-05-02 | 2017-11-09 | Clearside Biomedical, Inc. | Systems and methods for ocular drug delivery |
CA3072847A1 (en) | 2016-08-12 | 2018-02-15 | Clearside Biomedical, Inc. | Devices and methods for adjusting the insertion depth of a needle for medicament delivery |
US20180092776A1 (en) | 2016-09-30 | 2018-04-05 | Sara Heikali | Method and device for treating and managing diseased ocular tissue |
EP3547898A4 (en) | 2016-12-02 | 2020-07-08 | Oculeve, Inc. | APPARATUS AND METHOD FOR PREDICTING EYE DROUGHT AND TREATMENT RECOMMENDATION |
US10568735B2 (en) | 2017-01-13 | 2020-02-25 | Alcon Inc. | Intraocular lens injector |
US11000367B2 (en) | 2017-01-13 | 2021-05-11 | Alcon Inc. | Intraocular lens injector |
CN110573117B (zh) | 2017-10-06 | 2021-10-26 | 格劳科斯公司 | 用于递送多个眼部植入物的系统和方法 |
USD846738S1 (en) | 2017-10-27 | 2019-04-23 | Glaukos Corporation | Implant delivery apparatus |
KR20200093581A (ko) | 2017-11-21 | 2020-08-05 | 포사이트 비젼4, 인크. | 확장 가능한 포트 전달 시스템을 위한 유체 교환 기기 및 사용 방법 |
JP2022516917A (ja) * | 2019-01-04 | 2022-03-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 眼の血管新生を促進するための組成物および方法 |
NL2023743B1 (en) * | 2019-09-02 | 2021-05-12 | Medical Workshop B V | Ocular injection assist device |
WO2022172086A1 (en) * | 2021-02-09 | 2022-08-18 | Gyroscope Therapeutics Limited | Suprachoroidal injection device |
KR102421848B1 (ko) * | 2021-08-17 | 2022-07-19 | 김명배 | 주사기 보조기구 |
IL293586A (en) * | 2022-06-02 | 2024-01-01 | Medical Res Development Fund For Health Services Poriya Hospital | Syringe for eyes and method |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3880163A (en) * | 1973-10-26 | 1975-04-29 | Jack H Ritterskamp | Medicinal syringe actuating device |
US4258713A (en) * | 1979-07-23 | 1981-03-31 | Wardlaw Stephen C | Automatic disposable hypodermic syringe |
US5266562A (en) * | 1987-11-19 | 1993-11-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-inflammatory agents |
SG49173A1 (en) * | 1992-04-10 | 1998-05-18 | Keravision Inc | Corneal vacuum centering guide and dissector |
US5770589A (en) * | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
US5358491A (en) | 1993-09-13 | 1994-10-25 | Sterling Winthrop Inc. | Cartridge-needle unit having retractable needle |
US6309374B1 (en) | 1998-08-03 | 2001-10-30 | Insite Vision Incorporated | Injection apparatus and method of using same |
US6428528B2 (en) * | 1998-08-11 | 2002-08-06 | Antares Pharma, Inc. | Needle assisted jet injector |
DE29912965U1 (de) * | 1999-07-24 | 1999-09-16 | Hoelzle Dieter Tech Projekte | Injektionsvorrichtung |
AUPQ496500A0 (en) * | 2000-01-06 | 2000-02-03 | University Of Sydney, The | Kit |
US20020143284A1 (en) * | 2001-04-03 | 2002-10-03 | Hosheng Tu | Drug-releasing trabecular implant for glaucoma treatment |
US6613025B1 (en) * | 2000-05-25 | 2003-09-02 | Scimed Life Systems, Inc. | Method and apparatus for diagnostic and therapeutic agent delivery |
US6569853B1 (en) * | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
US6693125B2 (en) | 2001-01-24 | 2004-02-17 | Combinatorx Incorporated | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
NZ530764A (en) | 2001-07-09 | 2008-07-31 | Combinatorx Inc | Composition comprising a tricyclic antidepressant and a corticosteroid administered simutaneously or within 14 days for treatment of inflammatory disorders |
FR2842112B1 (fr) | 2002-07-12 | 2005-05-13 | Becton Dickinson France | Accessoire pour seringue |
IL157981A (en) * | 2003-09-17 | 2014-01-30 | Elcam Medical Agricultural Cooperative Ass Ltd | Auto injector |
JP4343730B2 (ja) * | 2004-02-19 | 2009-10-14 | オリンパス株式会社 | 内視鏡用処置具 |
JP4791009B2 (ja) * | 2004-06-25 | 2011-10-12 | 株式会社ニデック | 硝子体手術用コンタクトレンズ保持リング |
US20060047250A1 (en) * | 2004-08-30 | 2006-03-02 | Hickingbotham Dyson W | Fluid delivery device |
JP2008539036A (ja) * | 2005-04-26 | 2008-11-13 | バイオレーズ テクノロジー インコーポレイテッド | 眼の症状を治療するための装置 |
US20070005016A1 (en) * | 2005-06-20 | 2007-01-04 | Williams David F | Ocular injection device and method |
JP4877570B2 (ja) * | 2005-07-04 | 2012-02-15 | Hoya株式会社 | 硝子体手術用コンタクトレンズ保持リング |
JP5011542B2 (ja) * | 2005-10-31 | 2012-08-29 | 国立大学法人 長崎大学 | 硝子体内注射用固定具 |
-
2008
- 2008-01-09 EP EP08707847.3A patent/EP2124857B1/en active Active
- 2008-01-09 DK DK08707847.3T patent/DK2124857T3/en active
- 2008-01-09 CA CA2674891A patent/CA2674891C/en not_active Expired - Fee Related
- 2008-01-09 CA CA2674877A patent/CA2674877C/en not_active Expired - Fee Related
- 2008-01-09 WO PCT/EP2008/050206 patent/WO2008084064A1/en active Application Filing
- 2008-01-09 US US12/520,940 patent/US8460242B2/en not_active Expired - Fee Related
- 2008-01-09 DK DK08707846.5T patent/DK2124856T3/en active
- 2008-01-09 US US12/522,619 patent/US9308125B2/en active Active
- 2008-01-09 JP JP2009545174A patent/JP5201744B2/ja active Active
- 2008-01-09 WO PCT/EP2008/050203 patent/WO2008084063A1/en active Application Filing
- 2008-01-09 JP JP2009545173A patent/JP5201743B2/ja not_active Expired - Fee Related
- 2008-01-09 EP EP08707846.5A patent/EP2124856B1/en not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
EP2124856B1 (en) | 2018-10-17 |
US8460242B2 (en) | 2013-06-11 |
EP2124857A1 (en) | 2009-12-02 |
CA2674877A1 (en) | 2008-07-17 |
US9308125B2 (en) | 2016-04-12 |
JP5201743B2 (ja) | 2013-06-05 |
CA2674891C (en) | 2016-03-15 |
EP2124856A1 (en) | 2009-12-02 |
JP2010515504A (ja) | 2010-05-13 |
CA2674877C (en) | 2016-03-15 |
CA2674891A1 (en) | 2008-07-17 |
DK2124857T3 (en) | 2017-07-03 |
WO2008084064A1 (en) | 2008-07-17 |
WO2008084063A1 (en) | 2008-07-17 |
DK2124856T3 (en) | 2019-02-11 |
US20100010452A1 (en) | 2010-01-14 |
EP2124857B1 (en) | 2017-03-29 |
US20100030150A1 (en) | 2010-02-04 |
JP2010515505A (ja) | 2010-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5201744B2 (ja) | 眼内注射装置 | |
CA2498489C (en) | Method for subretinal administration of therapeutics including steroids;method for localizing pharmacodynamic action at the choroid and the retina; and related methods for treatment and/or prevention of retinal diseases | |
US7794437B2 (en) | Reservoirs with subretinal cannula for subretinal drug delivery | |
JP2022119912A (ja) | ヒト被験体における眼部障害の処置のための方法およびデバイス | |
US6413245B1 (en) | Sub-tenon drug delivery | |
JP4261343B2 (ja) | 眼薬投与装置 | |
JP2019501200A (ja) | 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス | |
US20070244442A1 (en) | Device for Ophthalmic Drug Delivery | |
JP2009508593A (ja) | 眼科用シリンジ | |
CN1805719A (zh) | 眼药输送装置 | |
CN219721047U (zh) | 用于递送植入物的注射器 | |
KR101750651B1 (ko) | 약물 잔류 방지능 및 재충전 기능을 갖는 안구 내 약물 주입 장치 | |
RU2281070C2 (ru) | Способ стабилизации внутриглазного давления в послеоперационном периоде антиглаукоматозных операций фильтрующего типа |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120731 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121030 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121106 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121128 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121205 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130115 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130208 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5201744 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160222 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |